通化东宝(600867):未来10年有望实现百亿销售额耗资7亿元的胰岛素二期已建成、调试完毕,胰岛素大扩产准备就绪,6月试产并申报GMP认证,7月份产品有望上市销售,产能包含3吨胰岛素原料药和年产3000万支制剂。胰岛素二期生产工艺系统优于一期,也优于诺和、礼莱两大巨头。 Tonghua Dongbao (600,867): the next 10 years is expected to achieve billions of sales of 700 million yuan in insulin cost has completed the second phase, commissioning is completed, insulin production expansion is ready, trial production in June and declare GMP certification in July is expected to It is marketed and has a capacity of 3 tons of API and an annual output of 30 million. Insulin two production process system is better than one, but also superior to Novo, Lilly two giants.